Study of Transpulmonary Mechanical Power to Predict Outcomes in Adults With Severe Acute Respiratory Distress Syndrome Using Venovenous ECMO

What this Trial Is About

Researchers are studying patients with severe acute respiratory distress syndrome ARDS who are receiving venovenous extracorporeal membrane oxygenation VV-ECMO support. The study aims to explore how transpulmonary mechanical power, which measures the energy delivered directly to lung tissue during mechanical ventilation, may predict the prognosis of these patients. Despite advances in VV-ECMO treatment, mortality remains high, and understanding mechanical powers role could improve patient outcomes. The study observes the use of transpulmonary pressure to guide ventilator settings in patients with severe ARDS treated with VV-ECMO. This observational approach monitors patients receiving standard VV-ECMO support, focusing on how transpulmonary mechanical power influences their treatment process. No experimental drugs or additional interventions are mentioned. Participants will be monitored for their ability to be successfully weaned from VV-ECMO within 60 days after enrollment. Researchers will also track 60-day mortality rates. The study involves collecting clinical data related to ventilation settings, patient response, and outcomes during and after VV-ECMO treatment. The total observation period for outcome assessment is 60 days post-enrollment.

Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO